Product Images Metformin Hydrochloride

The text provides a summary of mean percent changes in major lipid variables at the final visit of a 24-week study comparing the effectiveness of different formulations of Metformin hydrochloride tablets (extended release and otherwise) administered in doses of either 500mg twice daily, 1000mg or 1500mg once daily. The results show the changes in Total Cholesterol (mg/dL), Total Triglycerides (mg/dL), LDL-Cholesterol (mg/dL) and HDL-Cholesterol (mg/dL) for each formulation at different doses.*

The text provides a summary of mean changes in HbAs, fasting plasma glucose, and body weight in a 24-week study of metformin hydrochloride extended release tablets. Table 7 displays the results in patients taking 500mg, 1000mg, and 1500mg of the tablets twice or once a day. It shows baseline measurements and changes at 12 weeks and the final visit. The number of patients in each group varies from 66 to 74.*

This is a summary table depicting the mean percentage of the major lipid variables at the final visit of the 29-week studies comparing Metformin hydrochloride tablets with a placebo and the combination of Metformin hydrochloride with Glyburide. The variables included in the table are total cholesterol, total triglycerides, LDL-cholesterol, and HDL-cholesterol. The table compares the percentage change from baseline and the mean value of each variable at the final visit.*

NuCare Pharmaceuticals' Metformin HCI 850mg tablets come in a package of 120 tablets with lot number 000000 and NDC number 68071-4669-02. Each tablet contains 850mg of Metformin Hydrochloride, USP. The tablets are round and white or off-white with debossing "*H/103" on one side. The expiration date is 00-00, and the product should be stored at a controlled temperature of 59-86°F. Patients should contact their physician for medical advice about side effects, and any side effects should be reported to the FDA.*

This text describes the characteristics of a group of pediatric patients who were all on a diet therapy at baseline. The mean age of these patients was 13.8 years, with a range of 10 to 16 years. The text also indicates that there was no statistically significant difference between patients.*

This is a summary of a 29-week study comparing Metformin Hydrochloride tablets with a placebo. The study recorded mean changes from baseline in fasting plasma glucose (FPG), hemoglobin A, and body weight. The placebo group had 141 participants while the Metformin Hydrochloride Tablets group had 145 participants. The results showed a statistically significant change in FPG and Hemoglobin A, with the Metformin group showing a greater reduction. There was no statistically significant change in body weight. All patients were on diet therapy at the baseline.*

This is a summary table comparing Metformin Hydrochloride Tablets to Placebo in Pediatrics to observe changes in plasma glucose and body weight. The table includes the number of participants and their baseline measurements for both groups, as well as the mean changes from baseline to final visit. The Metformin group had a higher increase in plasma glucose and body weight compared to the Placebo group, with a significant p-value. The abbreviation NS suggests that there was no significant difference in body weight changes between the two groups.*

The table presents a 23-week study comparing the efficacy of combining Metformin Hydrochloride Tablets and Glyburide (Comb) versus only Glyburide (Glyb) or Metformin Hydrochloride Tablets (MET) Monotherapy. The summary of mean changes from baseline is shown for fasting plasma glucose, hemoglobin A1c, and body weight at the final visit. The statistical significance of the changes is indicated by p-values, and for some variables, the changes were not statistically significant.*

The table presents data on the summary of mean changes from baseline in HbA and daily insulin dose for a study comparing combined metformin hydrochloride tablets and insulin to placebo insulin. The data shows the treatment difference, with statistically significant results for metformin hydrochloride tablets/insulin compared to placebo insulin in terms of change in HbA1c levels, but not for daily insulin dose.*